Andrew S. Mendiola

Andrew S. Mendiola

Auto-generated profile, based on publicly available information

Andrew S. Mendiola

Gladstone Institutes, San Francisco, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2017 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
AMAndrew S. Mendiola
Andrew S. Mendiola
ACAstrid E. Cardona
Astrid E. Cardona

15 October 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JRJae Kyu Ryu
Jae Kyu Ryu
VRVictoria A. Rafalski
Victoria A. Rafalski
AMAnke Meyer-Franke
Anke Meyer-Franke
RARyan A. Adams
Ryan A. Adams
SPSuresh B. Poda
Suresh B. Poda
KAKaterina Akassoglou
Katerina Akassoglou

13 April 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
AMAndrew S. Mendiola
Andrew S. Mendiola
Jae Kyu RyuJae Kyu Ryu
Jae Kyu Ryu
SBSophia Bardehle
Sophia Bardehle
AMAnke Meyer-Franke
Anke Meyer-Franke
KAKenny Kean-Hooi Ang
Kenny Kean-Hooi Ang
KAKaterina Akassoglou
Katerina Akassoglou

1 December 2017 in Neuron
Verified
Journal Article
Closed access
MPMark A. Petersen
Mark A. Petersen
JRJae Kyu Ryu
Jae Kyu Ryu
KCKae-Jiun Chang
Kae-Jiun Chang
AEAinhoa Etxeberria
Ainhoa Etxeberria
SBSophia Bardehle
Sophia Bardehle
KAKaterina Akassoglou
Katerina Akassoglou

14 December 2020 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MMMario Merlini
Mario Merlini
VRVictoria A. Rafalski
Victoria A. Rafalski
KMKeran Ma
Keran Ma
KKKeun-Young Kim
Keun-Young Kim
EBEric Bushong
Eric Bushong
KAKaterina Akassoglou
Katerina Akassoglou

28 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
Jae Kyu RyuJae Kyu Ryu
Jae Kyu Ryu
ZYZhaoqi Yan
Zhaoqi Yan
MMMauricio Montano
Mauricio Montano
ESElif G. Sozmen
Elif G. Sozmen
KDKaruna Dixit
Karuna Dixit
KAKaterina Akassoglou
Katerina Akassoglou
Life-threatening thrombotic events and neurological symptoms are prevalent in COVID-19 and are persistent in patients with long COVID experiencing post-acute sequelae of SARS-CoV-2 infection1–4. Despite the clinical evidence1,5–7, the underlying mechanisms of coagulopathy in COVID-19 and its consequences in inflammation and neuropathology remain poorly understood and treatment options are insufficient. Fibrinogen, the central structural component of blood clots, is abundantly deposited in the lungs and brains of patients with COVID-19, correlates with disease severity and is a predictive biomarker for post-COVID-19 cognitive deficits1,5,8–10. Here we show that fibrin binds to the SARS-CoV-2 spike protein, forming proinflammatory blood clots that drive systemic thromboinflammation and neuropathology in COVID-19. Fibrin, acting through its inflammatory domain, is required for oxidative stress and macrophage activation in the lungs, whereas it suppresses natural killer cells, after SARS-CoV-2 infection. Fibrin promotes neuroinflammation and neuronal loss after infection, as well as innate immune activation in the brain and lungs independently of active infection. A monoclonal antibody targeting the inflammatory fibrin domain provides protection from microglial activation and neuronal injury, as well as from thromboinflammation in the lung after infection. Thus, fibrin drives inflammation and neuropathology in SARS-CoV-2 infection, and fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute COVID-19 and long COVID.